As expected, Pfizer submitted its new drug application (NDA) to the FDA for palbociclib seeking approval of the drug in breast cancer based on Phase II data from the firm's PALOMA-1 trial.
Pfizer seeks to market palbociclib in ER+/HER- breast cancer
As expected, Pfizer submitted its new drug application (NDA) to the FDA for palbociclib seeking approval of the drug in breast cancer based on Phase II data from the firm's PALOMA-1 trial.
More from Cardiovascular
More from Therapy Areas
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
• By
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
• By
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.